Clinical, genetic and functional characteristics of three novel CYP17A1 mutations causing combined 17alpha-hydroxylase/17,20-lyase deficiency by Rosa, S et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2010
Clinical, genetic and functional characteristics of three novel CYP17A1
mutations causing combined 17alpha-hydroxylase/17,20-lyase deficiency
Rosa, S; Steigert, M; Lang-Muritano, M; l’Allemand, D; Schoenle, E J; Biason-Lauber, A
Abstract: BACKGROUND: P450c17 has two distinct activities: 17alpha-hydroxylase activity and 17,20-
lyase activity. Combined 17alpha-hydroxylase/17,20-lyase deficiency leads to a severe defect in the pro-
duction of cortisol and sex steroids. In affected males this results in impaired masculinization with
ambiguous or female external genitalia. Female patients have normal genitalia but show a lack of puber-
tal development in adolescence. An increased production of mineralocorticoids often leads to hypertension
and hypokalemia in both sexes. METHODS: To better understand the mechanisms of P450c17 deficiency,
we studied 2 patients (both 46,XY) with combined 17alpha-hydroxylase/17,20-lyase deficiency of different
severity: one with complete lack of masculinization and one with ambiguous genitalia. RESULTS: Four
mutations were identified by sequencing of the CYP17A1 gene: I332T and A355T in the less severely
affected patient; G111S and R440H in the patient with complete lack of masculinization. The three novel
mutations were expressed in COS1 cells and all mutant proteins except I332T showed a complete loss
of both enzymatic activities. I332T retained some residual 17alpha-hydroxylase as well as 17,20-lyase
activity. CONCLUSION: We identified 2 patients with the phenotypical spectrum of P450c17 deficiency.
Three novel mutations in the CYP17A1 gene were identified and their functional characterization provided
a good phenotype-genotype correlation. The location of the mutated residues in the three-dimensional
model of P450c17 gave some additional insights into its structure-function relationship.
DOI: 10.1159/000284362
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-44373
Published Version
Originally published at:
Rosa, S; Steigert, M; Lang-Muritano, M; l’Allemand, D; Schoenle, E J; Biason-Lauber, A (2010).
Clinical, genetic and functional characteristics of three novel CYP17A1 mutations causing combined
17alpha-hydroxylase/17,20-lyase deficiency. Hormone Research in Paediatrics, 73(3):198-204. DOI:
10.1159/000284362
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Original Paper 
 Horm Res Paediatr 2010;73:198–204  
 DOI: 10.1159/000284362 
 Clinical, Genetic and Functional Characteristics
of Three Novel  CYP17A1 Mutations Causing 
Combined 17  -Hydroxylase/17,20-Lyase Deficiency 
 S. Rosa    M. Steigert    M. Lang-Muritano    D. l’Allemand    E.J. Schoenle    
A. Biason-Lauber 
 University Children’s Hospital, Zurich, Switzerland 
hydroxylase as well as 17,20-lyase activity.  Conclusion: We 
identified 2 patients with the phenotypical spectrum of 
P450c17 deficiency. Three novel mutations in the  CYP17A1 
gene were identified and their functional characterization 
provided a good phenotype-genotype correlation. The lo-
cation of the mutated residues in the three-dimensional 
model of P450c17 gave some additional insights into its 
structure-function relationship. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 The enzyme P450c17 plays an important role in steroid 
production. It is essential for the synthesis of cortisol as 
well as the production of sex steroids. P450c17 has two dis-
tinct activities: 17  -hydroxylase activity and 17,20-lyase 
activity, and is encoded by a single gene,  CYP17A1 , which 
consists of 8 exons  [1 ; accession No. HUMP45C17S]. Muta-
tions in the gene  CYP17A1 leading to P450c17 deficiency 
were first described 40 years ago by Biglieri et al.  [2] in a 
female and New  [3] in a male. Since then, mutations 
throughout the gene have been reported including rare 
cases of isolated 17,20-lyase deficiency [for details on al-
lelic variants, see OMIM 609300]. However, in most cases 
of P450c17 deficiency, both activities are reduced. Such 
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 Abstract 
 Background: P450c17 has two distinct activities: 17  -hy-
droxylase activity and 17,20-lyase activity. Combined 17  -
hydroxylase/17,20-lyase deficiency leads to a severe defect 
in the production of cortisol and sex steroids. In affected 
males this results in impaired masculinization with ambigu-
ous or female external genitalia. Female patients have nor-
mal genitalia but show a lack of pubertal development in 
adolescence. An increased production of mineralocorticoids 
often leads to hypertension and hypokalemia in both sexes. 
 Methods: To better understand the mechanisms of P450c17 
deficiency, we studied 2 patients (both 46,XY) with com-
bined 17  -hydroxylase/17,20-lyase deficiency of different 
severity: one with complete lack of masculinization and one 
with ambiguous genitalia.  Results: Four mutations were 
identified by sequencing of the  CYP17A1 gene: I332T and 
A355T in the less severely affected patient; G111S and R440H 
in the patient with complete lack of masculinization. The 
three novel mutations were expressed in COS1 cells and all 
mutant proteins except I332T showed a complete loss of 
both enzymatic activities. I332T retained some residual 17  -
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combined 17  -hydroxylase/17,20-lyase deficiency usually 
leads to a severe defect in the production of cortisol and 
sex steroids. In affected males this results in impaired mas-
culinization with ambiguous or female external genitalia. 
Female patients have normal genitalia but show a lack of 
pubertal development in adolescence. An increased pro-
duction of mineralocorticoids often leads to hypertension 
and hypokalemia in both sexes [for reviews, see  4, 5 ].
 We present clinical and molecular data of 2 patients 
with combined 17  -hydroxylase/17,20-lyase deficiency 
of different severity. Three novel mutations were identi-
fied and their functional consequences were investigated 
in expression studies.
 Materials and Methods 
 Patients 
 Patient 1 was a 7-week-old infant assigned to the female sex at 
birth who was referred for gender evaluation because of ambigu-
ous genitalia with an enlarged clitoris and posterior labial fusion 
(Prader III) and palpable gonads in the labia majora. The karyo-
type was 46,XY. Hormones measured in plasma and urine in bas-
al and stimulated (hCG) conditions suggested 17  -hydroxy-
lase/17,20-lyase deficiency: low basal and stimulated androgens 
(DHEA, androstenedione and testosterone), high progesterone 
and high mineralocorticoid precursors (deoxycorticosterone 
DOC and corticosterone B, and progesterone metabolites 16-OH-
pregnenolone).
 Treatment was initiated with 3 cycles of 50 mg testosterone 
depot, whereafter penile size increased from 5 to 37 mm allowing 
the surgeon to correct the genital defect and the patient was reas-
signed to the male sex at 4 months of age.
 Patient 2 was raised as a girl and accidentally diagnosed at age 
14 years when, during an appendectomy, no uterus and tubes were 
seen, hypertension with a blood pressure around 140/90 mm Hg 
and low potassium (3.0 mmol/l) were noted. She had no breast 
development and normal prepubertal female external genitalia 
but a blind-ending vagina. Due to bone age retardation, adult 
height prediction was increased to 187 cm. The karyotype was 
46,XY. Hormone values including an ACTH test were compatible 
with complete combined 17  -hydroxylase/17,20-lyase deficiency. 
Undescended testes were found and subsequently removed.
 The patient was treated with hydrocortisone, which had some 
lowering effect on blood pressure but nevertheless did not lead to 
satisfactory control of hypertension. Therefore, additional treat-
ment with spironolactone was necessary. The patient suffered 
from a depressive mental disorder and headaches but neither re-
placement therapy with hydrocortisone nor addition of estradiol 
to initiate pubertal development improved well-being. As the pa-
tient increased by herself hydrocortisone until overdose, the treat-
ment was stopped. Upon suspension of hydrocortisone a rise of 
corticosterone and a very high deoxycorticosterone level were 
noted, but adequacy of adrenal therapy with spironolactone alone 
was documented by normal blood pressure and normal plasma 
concentrations of potassium and ACTH. Yet after discontinua-
tion of hydrocortisone, the patient felt even more depressed and 
demanded to return to hydrocortisone treatment in addition to 
the above-mentioned therapy. The hormone values of both pa-
tients are summarized in  table 1 and  figure 1 a.
Table 1. Plasma basal and stimulated hormones
Hormone Patient 1 (7 months) Patient 2 (14 years)
basal normal
values
after hCG
stimulation
basal normal
values1
after ACTH
stimulation
LH, U/l 2.5 0.0–1.0 n.a. 48.6 5–25 n.a.
FSH, U/l 35 0.0–28 n.a. 93 4–20 n.a.
Progesterone, nmol/l 22.9 0.09–1.0 n.d. 32 0.3–1.5 65
17-OH-progesterone, nmol/l 5.1 0.3–9.5 5.3 0.74 0.3–4.7 0.76
DHEA, nmol/l 0.6 0.9–4.5 3.02 4.67 7.8–21.2 3.97
Androstenedione, nmol/l 0.33 0.5–2.5 0.8 0.1 1.4–7.9 0.1
Testosterone, nmol/l 0.1 4–14 1.1 <0.1 0.31–0.83 0.1
Estradiol, pmol/l 22 30–65 n.d. <20 72–250 n.d.
Cortisol, nmol/l 82 70–550 n.a. 15 70–550 60
ACTH, ng/l 40 10–55 n.a. 257 10–55 n.a.
(Tetrahydro)corticosterone 
(THB), g/24 h * n.a. 8,450 0–319 n.d.
Allo-THB, g/24 h * n.a. 1,1470 84–1,034 n.d.
16-OH-pregnenolone * n.a. 1,991 0–35 n.d.
n.a. = Not applicable; n.d. = not determined; * = see qualitative profile.
1 From Wudy and Homoki [14].
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 Mutation Analysis 
 Genomic DNA was extracted from peripheral blood leuko-
cytes using the Qiagen DNA blood and cell culture kit (Qiagen 
GmbH, Hilden, Germany) and used to perform polymerase chain 
reaction (PCR) exonic amplification of the  CYP17 gene as previ-
ously described  [6] . The PCR products were sequenced using the 
Big Dye Terminator Cycle Sequencing Kit and analyzed on an ABI 
Prism 310 Genetic Analyzer (Applied Biosystems; reference se-
quence: HUMP45C17S [cf.  1 ]). Primer sequences are available 
upon request.
 Expression Studies 
Wild-type  CYP17A1 cDNA (originally from Michael R. Water-
man), after addition of an N-terminal myc-tag, was inserted into
a pcDNA3.1 vector. Mutant cDNAs were constructed using the 
QuikChange II site-directed mutagenesis kit from Stratagene. In-
troduction of the mutations was confirmed by sequencing. Wild-
type or mutant cDNA was transiently transfected into confluent 
COS-1 cells using TransFast transfection reagent (32   l transfec-
tion reagent/3.6   g DNA). To standardize the steroid production, 
cells were cotransfected 1: 2 with BGal. Forty-eight hours after 
transfection, steroidogenic precursors (progesterone for 17  -hy-
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 Fig. 1.  a Qualitative urinary steroid profile of patient 1 compared 
to an age-matched control (Control). Only the peaks essential for 
the diagnosis (arrows) are labeled. The mineralocorticoid precur-
sors tetrahydrodeoxycorticosterone (THDOC) tetrahydrocom-
pound A (THA), tetrahydrocorticosterone (THB) and allo-THB 
are significantly high (and absent in the normal control). Com-
patible with an androgen synthesis defect, all the androgens in 
particular DHEA metabolites (16-OH-DHEA and isomers) are 
absent in patient 1 and very high in the normal control infant. 
IS = Internal standard (androstanediol).  b DNA sequence chro-
matograms obtained by direct sequencing of  CYP17A1  PCR prod-
ucts showing the presence of the heterozygote c.T1055C and
c.G1123A both in exon 6 leading to p.I332T and p.A355T, respec-
tively, in patient 1, and c.G391A in exon 2 of patient 2 leading to 
p.G111S. The c.G1379A (p.R440H) mutation was not further char-
acterized and is not shown. 
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droxylase activity and 17-OH-pregnenolone for 17,20-lyase activ-
ity) were added at concentrations of 0.1 and 1.0   M . Six hours after 
addition of the precursor, supernatants were removed and kept 
 frozen at –20 ° C until measured.   -Galactosidase activity was 
 measured using the   -galactosidase enzyme assay system (Pro-
mega). The secreted steroids, 17-OH-progesterone (reflecting 17  -
hydroxy lase activity) and DHEA (reflecting 17,20-lyase activity), 
were measured in duplicates by radioimmunoassay using commer-
cial kits from Diagnostic System Laboratories (Morwell Diagnos-
tics GmbH, Egg, Switzerland). Values were standardized for   -
galactosidase activity and expressed as percentage of wild-type ac-
tivity.
 All values are expressed as mean  8 SD and represent the re-
sults of three independent experiments.
 For mutation, I332T and the wild-type K m and V max were as-
sayed by exposing the transfected cells to six different precursor 
concentrations ranging from 0.1 to 30   M . The products were 
measured as described above. K m and V max were calculated using 
GraphPad Prism 4. Immunofluorescence was performed as previ-
ously described  [7] .
 Results 
 In patient 1, sequencing of the  CYP17A1 gene revealed 
the presence of a compound heterozygosity consisting of 
a c.T1055C and c.G1123A (reference mRNA NM_000102) 
leading to p.I332T and p.A355T respectively ( fig. 1 b). The 
parents are heterozygote (not shown). In order to assess 
the functional consequence of the mutations, COS1 cells 
were transfected with the expression vector pcDNA3 
containing either wild-type or mutant  CYP17A1 cDNA.
 The A355T mutant protein expressed in COS1 cells 
showed a complete loss of 17  -hydroxylase as well as 
17,20-lyase activity. In contrast, compared to the wild-
type  protein, the I332T mutant seems to retain 15–25% 
of 17  -hydroxylase and about 10% of 17,20-lyase activity 
at two different substrate concentrations (0.1 and 1.0 
  mol/l; see  fig. 3 ). The residual activity of the I332T mu-
tant was therefore further explored by using six different 
precursor concentrations in the transfected COS1 cells, 
and although classical enzyme kinetic is not possible in a 
whole-cell system, apparent K m and V max were calculated 
from the resulting concentrations of 17-OHP and DHEA. 
The results confirm that I332T retains some 17  -hydrox-
ylase (K cat WT vs. Mut: 79 vs. 4, vector 0.5) as well as some 
17,20-lyase activity (K cat WT vs. Mut: 128 vs. 10, vector 
incalculable), where the relative residual activity of the 
mutant is lower with higher precursor concentrations 
( fig. 2 ;  table 2 ).
 Patient 2 was also found to be a compound heterozy-
gote carrying a c.G391A in exon 2 with the consequent 
replacement of glycine-111 by serine (p.G111S;  fig. 1 b) as 
well as a c.G1379A substitution resulting in the R440H 
mutation. R440H has been characterized already in a pa-
tient with severe P450c17 deficiency and has been shown 
to have no 17  -hydroxylase or 17,20-lyase activity  [8] . Also 
the G111S mutation when expressed in COS1 cells lead to 
the synthesis of a protein with no residual ac tivity.
 Immunofluorescence microscopy demonstrated that 
the mutant proteins (G111S, A355T and I332T) were ex-
pressed in transfected COS1 cells in a fashion comparable 
to the wild-type protein, suggesting that the loss of enzy-
matic activity is not due to defects of synthesis, stability 
or localization of the P450c17 proteins. COS1 cells trans-
fected with the empty pcDNA3.1 vector did not express 
the P450c17 protein ( fig. 3 ). 
 Discussion 
 Patient 1 is a compound heterozygote bearing the mu-
tations A355T and I332T. A355T showed no activity in 
our expression studies in COS1 cells. However, mutation 
I332T seems to retain some residual activity (about 15% 
of 17  -hydroxylase and 10% of 17,20-lyase activity). In 
analogy with what was observed for CAH due to 21-hy-
droxylase deficiency, where compound heterozygotes for 
two different  CYP21 mutations usually have a phenotype 
compatible with the presence of the milder of the gene 
defects  [9] , it is feasible to hypothesize that the milder 
phenotype in this patient (subtle signs of masculiniza-
tion) is due to the presence of the I332T milder mutation. 
Residual activity in this mutation is not totally surprising 
as, according to the published structure of P450c17  [10, 
11] , I332 is not located within the active site. However, be-
ing near the end of the J helix it is not far upstream of the 
redox partner binding site and might well lead to some 
distortion of the redox partner binding surface resulting 
in the observed partial loss of activity. Similar to the 
E331del mutation we previously described  [7] and which 
also showed some residual activity, the effect of I332T on 
downstream structures might be dampened by the rela-
tively unstructured region at 337–341 between the J helix 
and the J  helix. A355T mutation is located in the K helix 
which is part of the redox partner binding site. It might 
have been expected to lead to a preferential loss of lyase 
activity with some hydroxylase activity preserved in con-
gruence to the reported mutations at R347 and R358, 
which were associated with isolated lyase deficiency  [12] . 
However, according to our expression studies, A355T 
seems to disrupt the structure of the protein so severely 
that all enzymatic activity is lost.
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17-Hydroxylase 17,20-Lyase
WT I332T vector WT I332T vector
Vmax, min–1 248 17.1 15.5 34.6 4.1 0.043
Km, mol 3.15 4.24 30 0.27 0.39 incalculable
Kcat 78.7 4.03 0.5 128 10.5 incalculable
Table 2. Kinetic of p.I332T
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 Fig. 2. Production of 17-OH-progesterone as a measure of 17  -
hydroxylase activity ( a ) and DHEA ( c ) as a measure of 17,20-lyase 
activity after 6 h incubation with different concentrations (0.1 and 
1   M ) of precursors (progesterone and 17-OH-pregnenolone, re-
spectively) in COS1 cells transfected with empty vector (vector), 
wild-type (WT) and mutated  CYP17A1 cDNAs. The data repre-
sent mean  8 SD of three independent experiments. For WT, vec-
tor and I332T mutant, apparent K m and V max  were calculated from 
the resulting concentrations of 17-OHP ( b ) and DHEA ( d ) after 
exposing transfected COS1 cells to different concentrations of 
precursors (0.1, 0.3, 1, 3, 10 and 30   M ). 
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 In patient 1 an additional difficulty was the decision 
about gender reassignment and whether micropenis 
therapy could be successful. Rapid diagnosis and involve-
ment of a multidisciplinary team allowed us finally to re-
assign the patient to the male sex at the age of 4 months. 
Treatment with 3 cycles of 50 mg testosterone depot re-
sulting in an increase of penile size from 5 to 37 mm al-
lowed the surgeon to correct the genital defect.
 Our patient 2 clinically and biochemically corresponds 
to complete 17  -hydroxylase/17,20-lyase deficiency. The 
severity of the phenotype is not surprising in light of the 
mutations found in this patient: G111S and R440H. The 
mutation R440H has been reported earlier in a patient of 
German origin with complete 17  -hydroxylase deficien-
cy and has been shown to lead to the synthesis of a protein 
with no detectable 17  -hydroxylase or 17,20-lyase activ-
ity  [8] . In our expression studies the mutation G111S al-
so caused a complete loss of both 17  -hydroxylase and 
17/20-lyase activities. G111S is located in the B  -C loop, a 
region of the protein that seems to be equally sensitive 
being part of the substrate entrance with the neighboring 
highly conserved I112 which is important for protein 
function  [11, 13] . In fact, displacement of I112 has been 
shown to completely destroy protein function  [10] . Sub-
 Fig. 3. Localization of wild-type and 
mutant myc-tagged  CYP17A1  cDNAs 
in transfected COS1 cells using an anti-
myc antibody. Cells transfected with 
an empty vector serve as negative con-
trol. Scale bar: 20   m. 
I332T
A355T
G111S
Wild-type
Empty vector
DAPI P450c17 (myc) Merge
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stitution of glycine-111 by serine might displace I112 
enough to abolish all enzymatic activity probably by dis-
rupting substrate binding. The importance of residue 111 
is confirmed by the severe phenotype and the report that 
a similar constructed mutant, G111D, completely lost en-
zymatic activity  [13] .
 Although she presented as a typical case of 17  -hy-
droxylase/17,20-lyase deficiency, management of patient 
2 proved to be difficult as, due to the rarity of the disorder, 
no real consensus on therapy exists. These patients do not 
suffer from cortisol deficiency and therefore do not need 
any cortisol substitution as the elevated corticosterone is 
sufficient to act as a substitute for cortisol. However, in 
order to treat the hypertension, low doses of glucocorti-
coids may be given in young children as their DOC levels 
should be readily suppressible with less than physiologic 
replacement doses. If a patient has not received glucocor-
ticoids in childhood and has had long-term DOC excess, 
the hypertension may become ‘fixed’ and be no longer 
sensitive to low-dose glucocorticoids and hence requires 
a mineralocorticoid antagonist such as spironolactone or 
the promising eplerenone which effectively prevent the 
blood pressure-increasing effect of the abundant miner-
alocorticoid precursors.
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